Sepsis Diagnostics Market

Sepsis Diagnostics Market Size, Market Forecast and Outlook By FMI

The sepsis diagnostics market was valued at USD 0.7 billion in 2025. The market is set to reach USD 0.7 billion by 2026-end and grow at a CAGR of 7.9% between 2026-2036 to reach USD 1.5 billion by 2036. Blood Culture Media will dominate with a 69.0% share, while Conventional Diagnostics will lead with a 63.0% share.

Sepsis Diagnostics Market Overview: Size and Forecast

• Sepsis Diagnostics Market Value (2026): USD 0.7 billion
• Sepsis Diagnostics Market Forecast Value (2036): USD 1.5 billion
• Sepsis Diagnostics Market Forecast CAGR (2026 to 2036): 7.9%
• Sepsis Diagnostics Market Leading Product: Blood Culture Media (69.0%)
• Sepsis Diagnostics Market Key Growth Regions: USA, UK, EU, Japan, South Korea
• Sepsis Diagnostics Market Key Players: bioMérieux SA, Roche Diagnostics, Thermo Fisher Scientific Inc., Danaher Corporation (Beckman Coulter), Immunexpress Inc.

Parameter	Details
Market Size in 2026 (Value)	USD 0.7 Billion
Market Forecast in 2036 (Value)	USD 1.5 Billion
CAGR (2026 to 2036)	7.9%
Years Considered	2021 to 2036
Base Year	2025
Forecast Period	2026 to 2036
Units Considered	Value (USD Billion)
Leading Sub-Region	USA

Summary of the Sepsis Diagnostics Market

• Demand and Growth Drivers
  • Hospitals, and Diagnostic Laboratories applications are expected to sustain procurement of blood culture media products as clinical protocols tighten and patient populations expand through 2036.
  • Conventional Diagnostics and automated diagnostics are projected to shape procurement patterns, with regulatory-approved formats capturing the largest volume share.
  • USA at 8.0% and South Korea at 8.0% are the fastest-growing markets, reflecting expanding institutional infrastructure and policy-driven adoption during the forecast period.
• Product and Segment View
  • Instruments is expected to account for 64.0% of the product segment in 2026, supported by demand across Aerobic Culture Media, Standard Aerobic Bottles, and Enhanced Recovery Media in clinical and diagnostic settings.
  • Instruments is projected to gain share during the forecast period as blood culture systems and automated detection systems applications expand across Hospitals, and Diagnostic Laboratories sectors.
  • By method, Conventional Diagnostics leads demand, reflecting a preference over automated diagnostics and alternatives across end-use buyers.
• Geography and Competitive Outlook
  • USA is projected to lead growth at 8.0% through 2036, driven by FDA regulatory pathway maturity, Medicare reimbursement structures, and high per-capita blood culture media utilization rates in hospital and ambulatory settings.
  • South Korea at 8.0% reflects MFDS regulatory frameworks, advanced hospital infrastructure, and domestic medical device OEM positions supporting blood culture media adoption.
  • bioMérieux SA and Roche Diagnostics lead the competitive field through regulatory approval breadth, clinical evidence portfolios, and institutional procurement contracts across high-volume markets.
• Analyst Opinion
  • Sabyasachi Ghosh, Principal Consultant at FMI says, 'Companies that can align instruments product portfolios with evolving hospitals requirements while maintaining cost-competitive pricing across instruments categories are expected to strengthen their procurement positions through the forecast period.'
  • The sepsis diagnostics market is shifting from a standardized supply model toward differentiated product portfolios where blood culture media performance, conventional diagnostics capability, and total cost of ownership shape purchasing decisions.
  • Adoption is increasing due to hospitals and diagnostic laboratories demand, regulatory protocol updates, and replacement of legacy assays and reagents configurations that no longer meet current requirements.
  • Demand is further supported by procurement consolidation among hospitals buyers and preference for suppliers combining blood culture media breadth with conventional diagnostics capability.

Sepsis Diagnostics Market Definition

The sepsis diagnostics market encompasses medical devices, consumables, and services used across Hospitals, Diagnostic Laboratories, and Research and Academic Institutes applications, serving Hospitals, and Diagnostic Laboratories sectors.

Sepsis Diagnostics Market Inclusions

Market scope encompasses all commercially traded sepsis diagnostics products categorized by product (Blood Culture Media, Instruments, and Assays and Reagents), method (Conventional Diagnostics, and Automated Diagnostics), pathogen (Gram Negative Bacterial Sepsis, Gram Positive Bacterial Sepsis, and Fungal Sepsis), technology (Microbiology, Molecular Diagnostics, and Immunoassays), end use (Hospitals, Diagnostic Laboratories, and Research and Academic Institutes). Revenue estimates cover the period from 2026 to 2036 across all regions and distribution channels.

Sepsis Diagnostics Market Exclusions

The scope does not include unregulated or non-commercial medical products, experimental devices without regulatory clearance, or services unrelated to sepsis diagnostics procurement and clinical deployment.

Sepsis Diagnostics Market Research Methodology

• Primary Research: FMI analysts conducted interviews with device manufacturers, clinical procurement specialists, hospital supply chain managers, and end-use operators across USA, South Korea, and EU to validate demand patterns and pricing structures for blood culture media and related product categories.
• Desk Research: Combined clinical trial registries, regulatory approval databases, reimbursement data, and manufacturer disclosures to establish baseline parameters for sepsis diagnostics across product and method segments.
• Market Sizing and Forecasting: Bottom-up aggregation across Blood Culture Media, Instruments, and Assays and Reagents product categories and Hospitals, Diagnostic Laboratories, and Research and Academic Institutes applications, triangulated with top-down macro indicators and regional adoption curves.
• Data Validation: Cross-checked quarterly against regulatory clearance volumes, hospital procurement records, and manufacturer revenue disclosures for sepsis diagnostics products.

Why is the Sepsis Diagnostics Market Growing?

• Applications in hospitals and diagnostic laboratories in both established and emerging markets consistently drive demand for blood culture media and instruments products.
• The USA shows the greatest growth at 8.0% due to the maturity of the FDA regulatory pathway, the structure of Medicare reimbursement, and the high per capita utilization of blood culture media in both hospital and ambulatory settings.
• Instruments segment is estimated to account for 64.0% of the product segment owing to the high demand for Aerobic Culture Media and Standard Aerobic Bottles configurations and wide applicability in clinical settings.

Sepsis diagnostics market is estimated at USD 0.7 Bn in 2026 and is projected to reach USD 1.5 Bn by 2036, registering a CAGR of 7.9%. The growth is attributed to the growing demand for Blood Culture Media, and Instruments in Hospitals, Diagnostic Laboratories and Research and Academic Institutes applications. The incremental opportunity of USD 0.8 Bn between 2026 and 2036 is the cumulative impact of clinical adoption, regulatory compliance cycles and geographic expansion of procurement. Automated diagnostics are making inroads in niche applications, but Conventional Diagnostics remains the de facto processing paradigm.

Instruments is the top product category at 64.0% in 2026. Aerobic Culture Media, Standard Aerobic Bottles and Enhanced Recovery Media sub-categories have concentrated demand, each catering to different hospitals requirements. Instruments is a secondary growth category with Blood Culture Systems, and Automated Detection Systems sub-segments gaining traction as procurement diversifies.

Geographically, the US leads at 8.0% driven by the maturity of the FDA regulatory pathway, Medicare reimbursement structures and high per-capita utilization of blood culture media in hospital and ambulatory settings. The South Korea (8.0%) market is driven by MFDS regulatory frameworks, advanced hospital infrastructure and domestic medical device OEM positions supporting blood culture media adoption. Replacement and compliance cycles underpin demand in North America and Western Europe.

Market Segmentation Analysis

• Aerobic Culture Media and Standard Aerobic Bottles are the major procurement volumes for the Instruments product segment which leads the product segment at 64.0% in 2026 across clinical channels.
• By method, Conventional Diagnostics maps standard procurement trends in conventional diagnostics and automated diagnostics.
• Pathogen segmentation identifies gram negative bacterial sepsis as the primary channel reflecting institutional procurement structures and GPO relationships in high volume markets.

The sepsis diagnostics market is classified on the basis of product, method, pathogen, technology, and end use. Besides, the market also has Blood Culture Media, Instruments and Assays and Reagents as a by-product. All these have different procurement processes. The main categories are Conventional diagnostics and automated diagnostics by method.

Insights into the Blood Culture Media Segment

Blood Culture Media is dominating product segment with focused demand from hospital, diagnostics and outpatient settings. The key sub-categories are Aerobic Culture Media, Standard Aerobic Bottles, Enhanced Recovery Media and Anaerobic Culture Media which characterize the hospitals requirements and procurement specifications.

Selection of blood culture media is influenced by compatibility with clinical protocols, regulatory approval, and the institution’s formulary. The aerobic culture media sub-category is the leader in volume, and standard aerobic bottles is gaining share as diagnostic laboratories applications expand.

Insights into the Instruments Segment

The instrument segment is estimated to account for a share of 64.0%. Sub-categories include Blood Culture Systems, Automated Detection Systems, Continuous Monitoring Systems, and Molecular Diagnostic Instruments, catering to specialized requirements across Hospitals, and Diagnostic Laboratories applications.

Changing clinical protocols, updated regulatory requirements and growing demand for precision grade products in diagnostic laboratories settings are driving the adoption of instruments. Growth sub-categories such as Blood Culture Systems and automated detection systems are expected to dominate the forecast period.

Sepsis Diagnostics Market Drivers, Restraints, and Opportunities

• Applications in hospitals and diagnostic laboratories are the key structural drivers, creating recurring procurement cycles for blood culture media products through 2036.
• Price sensitive market segments are predominantly restricted by reimbursement constraints, institutional procurement pricing pressure and long regulatory approval timelines.
• Incremental procurement opportunities are expected through the forecast period, from point-of-care expansion, emerging market hospital modernization, and clinical protocol updates.

Structural demand from Applications of Hospitals, and Diagnostic Laboratories supports the sepsis diagnostics market. Processing still relies primarily on conventional diagnostics although automated diagnostics are making inroads in niche applications. Constraints include regulatory compliance costs and price pressure.

Hospitals Demand and Regulatory Procurement Cycles for Blood Culture Media

Demand for blood culture media has been created due to hospitals and diagnostic laboratories application requirements resulting in recurring procurement cycles. The volume is largely driven by Aerobic Culture Media and standard aerobic bottles sub-categories, with specifications driven by hospitals operator requirements and conventional diagnostics compatibility. Growth is driven by new adoption in growing markets and replacement of legacy products in established regions.

Pricing Pressure and Reimbursement Constraints on Instruments Adoption

Institutional pricing pressure and reimbursement constraints in emerging markets coupled with long regulatory approval timelines delay the introduction of new configurations, limiting instrument adoption. Hospital procurement committees prefer products that are already proven to be cost-effective over a defined clinical use cycle, which can be difficult for newer products that lack established reimbursement codes.

Emerging Market Expansion and Blood Culture Media Procurement Growth in USA

USA led growth at 8.0%, driven by the maturity of the FDA regulatory pathway, Medicare reimbursement structures, and high per-capita blood culture media utilization rates in both hospital and ambulatory settings. South Korea at 8.0% is driven by MFDS regulatory frameworks, advanced hospital infrastructure and domestic medical device OEM positions to support adoption of blood culture media. These markets will together be the major growth paths for blood culture media procurement until 2036, with hospitals and diagnostic laboratories applications holding the majority of the demand.

Analysis of Sepsis Diagnostics Market By Key Countries

Country	CAGR
USA	8.0%
South Korea	8.0%
EU	7.9%
Japan	7.9%
UK	7.8%

• USA at 8.0% reflects FDA regulatory pathway maturity, Medicare reimbursement structures, and high per-capita blood culture media utilization rates in hospital and ambulatory settings.
• South Korea at 8.0% reflects MFDS regulatory frameworks, advanced hospital infrastructure, and domestic medical device OEM positions supporting blood culture media adoption.
• EU at 7.9% reflects EU MDR regulatory transition, hospital modernization across member states, and centralized procurement structures for blood culture media products.

The global sepsis diagnostics market is projected to expand at 7.9% from 2026 to 2036. The study covers more than 30 countries, and the primary markets are listed below.

Demand Outlook for Sepsis Diagnostics Market in USA

Demand for sepsis diagnostics in USA is concentrated in hospitals and diagnostic laboratories applications, with the market projected to grow at 8.0% through 2036. Growth is attributable to FDA regulatory pathway maturity, Medicare reimbursement structures, and high per-capita blood culture media utilization rates in hospital and ambulatory settings.

• Procurement of blood culture media is concentrated in hospital and clinic channels, reflecting hospitals requirements and regulatory compliance standards in USA.
• Adoption of instruments is expanding across diagnostic and outpatient settings as clinical protocols evolve and hospitals buyers expand supplier qualification programs.
• Conventional diagnostics demand reflects clinical validation requirements and growing preference for regulatory-cleared blood culture media products with verified efficacy and safety data.

Future Outlook for Sepsis Diagnostics Market in South Korea

Government and regulatory frameworks in South Korea are creating structured procurement demand for blood culture media, with the market expanding at 8.0% through 2036. Demand reflects MFDS regulatory frameworks, advanced hospital infrastructure, and domestic medical device OEM positions supporting blood culture media adoption.

• Hospitals applications are generating volume for hospital and clinic channels, reflecting hospitals requirements and regulatory compliance standards in South Korea.
• Instruments procurement is supported by diagnostic and outpatient settings as clinical protocols evolve and hospitals buyers expand supplier qualification programs.
• Diagnostic laboratories demand is creating incremental opportunities for clinical validation requirements and growing preference for regulatory-cleared blood culture media products with verified efficacy and safety data.

Opportunity Analysis of Sepsis Diagnostics Market in EU

EU's healthcare infrastructure and institutional procurement base supports a growth rate of 7.9% through 2036 for sepsis diagnostics products. Procurement patterns reflect EU MDR regulatory transition, hospital modernization across member states, and centralized procurement structures for blood culture media products.

• Blood culture media demand is shaped by hospital and clinic channels, reflecting hospitals requirements and regulatory compliance standards in EU.
• Investment in hospitals is driving procurement of diagnostic and outpatient settings as clinical protocols evolve and hospitals buyers expand supplier qualification programs.
• Replacement cycles for legacy instruments configurations are supporting clinical validation requirements and growing preference for regulatory-cleared blood culture media products with verified efficacy and safety data.

In-depth Analysis of Sepsis Diagnostics Market in Japan

Regulatory requirements in Japan are shaping blood culture media procurement standards, with the market growing at 7.9% through 2036. Demand drivers include PMDA approval pathways, aging population demographics, and hospital automation investment supporting blood culture media demand.

• Institutional procurement of blood culture media reflects hospital and clinic channels, reflecting hospitals requirements and regulatory compliance standards in Japan.
• Diagnostic laboratories applications are accelerating adoption of diagnostic and outpatient settings as clinical protocols evolve and hospitals buyers expand supplier qualification programs.
• Supply chain development for instruments is expanding clinical validation requirements and growing preference for regulatory-cleared blood culture media products with verified efficacy and safety data.

Sales Analysis of Sepsis Diagnostics Market in UK

Infrastructure investment in UK is supporting sepsis diagnostics demand at 7.8% through 2036. Growth is led by NHS procurement frameworks, MHRA regulatory pathways, and hospital modernization programs creating demand for blood culture media.

• Volume demand for blood culture media is led by hospital and clinic channels, reflecting hospitals requirements and regulatory compliance standards in UK.
• Instruments adoption is supported by diagnostic and outpatient settings as clinical protocols evolve and hospitals buyers expand supplier qualification programs.
• Hospitals procurement is shifting toward clinical validation requirements and growing preference for regulatory-cleared blood culture media products with verified efficacy and safety data.

Competitive Landscape and Strategic Positioning

• bioMérieux SA has a strong presence in the sepsis diagnostics market with a large portfolio of regulatory clearances, clinical evidence, and established relationships with hospital procurement in USA, South Korea and EU.
• Roche Diagnostics, Thermo Fisher Scientific Inc. and Danaher Corporation (Beckman Coulter) maintain competitive positions with their specialized product lines in blood culture media and instruments categories.
• Emerging participants are focusing on niche clinical applications in hospitals and diagnostic labs segments to establish initial buying relationships..

bioMérieux SA is a leader in sepsis diagnostics, with a comprehensive portfolio of regulatory clearances and clinical validations across the FDA and EU MDR pathways. Roche Diagnostics has a good position with specialized instruments product lines.

Thermo Fisher Scientific Inc. & Danaher Corporation (Beckman Coulter) compete on product performance & institutional access. The barriers are regulatory timelines, clinical evidence and GPO contracts.

Strategic priorities for market leaders are expanding the blood culture media portfolio for diagnostic lab applications, speeding up regulatory submissions in emerging markets and reducing the cost of manufacturing per unit.

Key Companies in the Sepsis Diagnostics Market

Key global companies leading the sepsis diagnostics market include:

• bioMérieux SA, Roche Diagnostics, Thermo Fisher Scientific Inc., Danaher Corporation (Beckman Coulter), and Immunexpress Inc. maintain leading positions through established regulatory clearance portfolios, clinical evidence bases, and institutional procurement contracts across global markets.
• Other Sepsis Diagnostic Developers have built competitive positions in regional markets through specialized instruments product capabilities and focused distribution networks.
• Emerging entrants are targeting research and academic institutes applications and point-of-care segments to establish initial procurement positions and scale.

Competitive Benchmarking: Sepsis Diagnostics Market

Company	Blood Culture Media Range	Regulatory Coverage	Clinical Reach	Geographic Footprint
bioMérieux SA	High	High	Strong	Global
Roche Diagnostics	High	High	Strong	Global
Thermo Fisher Scientific Inc.	Medium	High	Moderate	Regional
Danaher Corporation (Beckman Coulter)	Medium	High	Moderate	Regional
Immunexpress Inc.	Medium	High	Moderate	Regional
Other Sepsis Diagnostic Developers	Medium	Medium	Low	Regional

Source: Future Market Insights competitive analysis, 2026.

Key Developments in Sepsis Diagnostics Market

• In 2025, bioMérieux further expanded its integrated sepsis diagnostics portfolio by upgrading its blood culture, pathogen identification and antimicrobial susceptibility testing (AST) workflow solutions to help hospitals accelerate sepsis detection and treatment decisions. The company also extended its comprehensive sepsis management pathway to hospital laboratories and critical-care areas.
• In 2025, Immunexpress presented new clinical data for SeptiCyte® RAPID at the Society of Critical Care Medicine (SCCM) Critical Care Congress demonstrating the test's ability to help clinicians differentiate sepsis from non-infectious systemic inflammatory response syndrome (SIRS) across various infection sites, supporting broader adoption of rapid host-response diagnostics..

Key Players in the Sepsis Diagnostics Market

Major Global Players

• bioMérieux SA
• Roche Diagnostics
• Thermo Fisher Scientific Inc.
• Danaher Corporation (Beckman Coulter)
• Immunexpress Inc.
• Other Sepsis Diagnostic Developers

Emerging Players/Startups

• Inflammatix
• Cytovale
• Prenosis
• Immunexpress
• PERSOWN Inc.
• Sepset Biosciences
• Entegrion

Report Scope and Coverage

Sepsis Diagnostics Market - Research Methodology

Method	Description
Primary Research	FMI analysts conducted interviews with device manufacturers, clinical procurement specialists, hospital supply chain managers, and end-use operators across USA, South Korea, and EU to validate demand patterns and pricing structures for blood culture media and related product categories.
Desk Research	Combined clinical trial registries, regulatory approval databases, reimbursement data, and manufacturer disclosures to establish baseline parameters for sepsis diagnostics across product and method segments.
Market Sizing & Forecasting	Bottom-up aggregation across Blood Culture Media, Instruments, and Assays and Reagents product categories and Hospitals, Diagnostic Laboratories, and Research and Academic Institutes applications, triangulated with top-down macro indicators and regional adoption curves.
Data Validation	Cross-checked quarterly against regulatory clearance volumes, hospital procurement records, and manufacturer revenue disclosures for sepsis diagnostics products.

Parameter	Details
Market size by 2036	USD 1.5 Billion
Growth rate	7.9% CAGR (2026 to 2036)
Forecast period	2026 to 2036
Base year value (2025)	USD 0.7 Billion
Key Segment Covered	Product, Method, Pathogen, Technology, End Use
Regions covered	North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, Middle East and Africa
Countries covered	USA, South Korea, Japan, UK, 30 plus countries
Key companies profiled	bioMérieux SA, Roche Diagnostics, Thermo Fisher Scientific Inc., Danaher Corporation (Beckman Coulter), Immunexpress Inc., Other Sepsis Diagnostic Developers

Market Segmentation Analysis

Sepsis Diagnostics Market Segmented by Product:

• Blood Culture Media
  • Aerobic Culture Media
    • Standard Aerobic Bottles
    • Enhanced Recovery Media
  • Anaerobic Culture Media
    • Anaerobic Bottles
    • Specialized Growth Media
  • Pediatric Culture Media
    • Low Volume Bottles
    • Fast Detection Media
• Instruments
  • Blood Culture Systems
    • Automated Detection Systems
    • Continuous Monitoring Systems
  • Molecular Diagnostic Instruments
    • Polymerase Chain Reaction Systems
    • Next Generation Sequencing Systems
  • Immunoassay Analyzers
    • Enzyme Linked Immunoassay Systems
    • Chemiluminescence Systems
• Assays and Reagents
  • Molecular Assays
    • Pathogen Detection Panels
    • Resistance Gene Detection
  • Immunoassay Reagents
    • Biomarker Detection Kits
    • Inflammatory Marker Assays
  • Microbiology Reagents
    • Culture Media Supplements
    • Staining Reagents

Sepsis Diagnostics Market Segmented by Method:

• Conventional Diagnostics
  • Culture Based Methods
    • Blood Culture Testing
    • Colony Identification
  • Biochemical Testing
    • Manual Identification
    • Phenotypic Testing
• Automated Diagnostics
  • Automated Blood Culture
    • Continuous Monitoring
    • Rapid Detection Systems
  • Automated Molecular Testing
    • High Throughput Systems
    • Integrated Platforms

Sepsis Diagnostics Market Segmented by Pathogen:

• Gram Negative Bacterial Sepsis
  • Enterobacteriaceae
    • Escherichia Coli
    • Klebsiella Species
  • Non Fermenting Bacteria
    • Pseudomonas Aeruginosa
    • Acinetobacter Species
• Gram Positive Bacterial Sepsis
  • Staphylococcus Infections
    • Staphylococcus Aureus
    • Coagulase Negative Staphylococci
  • Streptococcus Infections
    • Streptococcus Pneumoniae
    • Enterococcus Species
• Fungal Sepsis
  • Candida Infections
    • Candida Albicans
    • Non Albicans Candida
  • Other Fungal Pathogens
    • Aspergillus Species
    • Cryptococcus Species

Sepsis Diagnostics Market Segmented by Technology:

• Microbiology
  • Culture Based Technology
    • Manual Culture Methods
    • Automated Culture Systems
  • Staining and Identification
    • Gram Staining
    • Microscopy Techniques
• Molecular Diagnostics
  • Polymerase Chain Reaction
    • Real Time Polymerase Chain Reaction
    • Multiplex Polymerase Chain Reaction
  • Sequencing Technologies
    • Next Generation Sequencing
    • Targeted Sequencing
• Immunoassays
  • Enzyme Linked Immunoassays
    • Biomarker Detection
    • Inflammatory Markers
  • Chemiluminescence Assays
    • High Sensitivity Detection
    • Automated Testing

Sepsis Diagnostics Market Segmented by End Use:

• Hospitals
  • Intensive Care Units
    • Critical Care Testing
    • Emergency Diagnostics
  • General Wards
    • Routine Monitoring
    • Infection Screening
• Diagnostic Laboratories
  • Independent Laboratories
    • High Volume Testing
    • Specialized Diagnostics
  • Hospital Laboratories
    • In House Testing
    • Rapid Diagnostics
• Research and Academic Institutes
  • Clinical Research Centers
    • Sepsis Studies
    • Biomarker Research
  • Academic Institutes
    • Medical Research
    • Infectious Disease Research

Sepsis Diagnostics Market by Region:

• North America
  • USA
  • Canada
  • Mexico
• Latin America
  • Brazil
  • Chile
  • Rest of Latin America
• Western Europe
  • Germany
  • UK
  • Italy
  • Spain
  • France
  • Nordic
  • BENELUX
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • Hungary
  • Balkan & Baltic
  • Rest of Eastern Europe
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia & New Zealand
  • Rest of South Asia and Pacific
• Middle East & Africa
  • Kingdom of Saudi Arabia
  • Other GCC Countries
  • Türkiye
  • South Africa
  • Other African Union
  • Rest of Middle East & Africa

Research Sources and Bibliography

• 1. World Health Organization. (2025). WHO Global Report on Medical Device Access and Procurement Standards. WHO.
• 2. USA Food and Drug Administration. (2025). FDA Medical Device Classification and Clearance Database: Sepsis diagnostics Products. FDA.
• 3. European Medicines Agency. (2025). EMA Annual Report on Medical Device Regulation Under EU MDR. EMA.
• 4. International Medical Device Regulators Forum. (2025). IMDRF Guidance on Hospitals Device Classification. IMDRF.
• 5. Organisation for Economic Co-operation and Development. (2025). OECD Health Statistics: Hospitals Indicators. OECD.

This bibliography is provided for reader reference.

This Report Answers

• Estimating the size of the sepsis diagnostics market and revenue projections from 2026 to 2036.
• Segmentation by product, method, pathogen, technology, end use.
• Insights across more than 30 regional and country-level markets.
• Analysis of Hospitals, and Diagnostic Laboratories demand drivers, procurement patterns, and adoption dynamics.
• Assessment of the competitive landscape including bioMérieux SA, Roche Diagnostics, and Thermo Fisher Scientific Inc. and other participants.
• Identification of growth opportunities across blood culture media and instruments segments.
• Evaluation of supply chain dynamics, conventional diagnostics trends, and distribution channel structures.
• Delivery of data in PDF and Excel formats.